Although the antagonism of LPAR1/3 protects against podocyte loss in endothelial nitric oxide synthase (eNOS)−/− db/db mice, a type 2 diabetes model [15], the role of LPA/LPAR1 signaling in podocyte damage during DN remains unexplored. The gene discussed is NOS3; the disease is type 2 diabetes mellitus.